- Home
- NEWP vs NKTX Comparison
NEWP vs NKTX Comparison
Compare NEWP & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWP
- NKTX
- Stock Information
- Founded
- NEWP 1972
- NKTX 2015
- Country
- NEWP Canada
- NKTX United States
- Employees
- NEWP N/A
- NKTX N/A
- Industry
- NEWP
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- NEWP
- NKTX Health Care
- Exchange
- NEWP Nasdaq
- NKTX Nasdaq
- Market Cap
- NEWP 202.4M
- NKTX 170.8M
- IPO Year
- NEWP N/A
- NKTX 2020
- Fundamental
- Price
- NEWP $1.24
- NKTX $2.47
- Analyst Decision
- NEWP Strong Buy
- NKTX Strong Buy
- Analyst Count
- NEWP 1
- NKTX 5
- Target Price
- NEWP $5.00
- NKTX $15.20
- AVG Volume (30 Days)
- NEWP 245.4K
- NKTX 1.5M
- Earning Date
- NEWP 02-11-2025
- NKTX 11-07-2024
- Dividend Yield
- NEWP N/A
- NKTX N/A
- EPS Growth
- NEWP N/A
- NKTX N/A
- EPS
- NEWP N/A
- NKTX N/A
- Revenue
- NEWP N/A
- NKTX N/A
- Revenue This Year
- NEWP N/A
- NKTX N/A
- Revenue Next Year
- NEWP N/A
- NKTX N/A
- P/E Ratio
- NEWP N/A
- NKTX N/A
- Revenue Growth
- NEWP N/A
- NKTX N/A
- 52 Week Low
- NEWP $0.87
- NKTX $2.08
- 52 Week High
- NEWP $2.53
- NKTX $16.24
- Technical
- Relative Strength Index (RSI)
- NEWP 43.73
- NKTX 50.49
- Support Level
- NEWP $1.11
- NKTX $2.19
- Resistance Level
- NEWP $1.25
- NKTX $2.70
- Average True Range (ATR)
- NEWP 0.07
- NKTX 0.15
- MACD
- NEWP 0.01
- NKTX 0.03
- Stochastic Oscillator
- NEWP 65.79
- NKTX 54.90
About NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.